Home Blog of Signal Transduction Metabolism Carbonic Anhydrase Drug Repurposing Analysis for Colorectal Cancer through Network Medicine Framework: Novel Candidate Drugs and Small Molecules

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Drug Repurposing Analysis for Colorectal Cancer through Network Medicine Framework: Novel Candidate Drugs and Small Molecules

This study aimed to reveal the drug-repurposing candidates for colorectal cancer (CRC) via drug-repurposing methods and network biology approaches. A novel, differentially co-expressed, highly interconnected, and co-regulated prognostic gene module was identified for CRC. Based on the gene module, polyethylene glycol (PEG), gallic acid, pyrazole, cordycepin, phenothiazine, pantoprazole, cysteamine, indisulam, valinomycin, trametinib, BRD-K81473043, AZD8055, dovitinib, BRD-A17065207, and tyrphostin AG1478 presented as drugs and small molecule candidates previously studied in the CRC. Lornoxicam, suxamethonium, oprelvekin, sirukumab, levetiracetam, sulpiride, NVP-TAE684, AS605240, 480743.cdx, HDAC6 inhibitor ISOX, BRD-K03829970, and L-6307 are proposed as novel drugs and small molecule candidates for CRC.

 

Comments:

It looks like you provided a summary of a study that aimed to identify drug-repurposing candidates for colorectal cancer (CRC) using various methods including network biology approaches. The study identified a novel gene module associated with CRC and proposed several drugs and small molecules as potential candidates for repurposing in CRC treatment.

The mentioned repurposing candidates include:

**Previously Studied Candidates:**
1. Polyethylene glycol (PEG)
2. Gallic acid
3. Pyrazole
4. Cordycepin
5. Phenothiazine
6. Pantoprazole
7. Cysteamine
8. Indisulam
9. Valinomycin
10. Trametinib
11. BRD-K81473043
12. AZD8055
13. Dovitinib
14. BRD-A17065207
15. Tyrphostin AG1478

**Novel Candidates:**
1. Lornoxicam
2. Suxamethonium
3. Oprelvekin
4. Sirukumab
5. Levetiracetam
6. Sulpiride
7. NVP-TAE684
8. AS605240
9. 480743.cdx
10. HDAC6 inhibitor ISOX
11. BRD-K03829970
12. L-6307

These candidates have been identified based on their association with the identified gene module and their potential for repurposing in the treatment of colorectal cancer. Further research and clinical studies would be necessary to validate their efficacy and safety for CRC patients.

Related Products

Cat.No. Product Name Information
S9742 Indisulam Indisulam (E7070), a sulfonamide anticancer agent, is a potent carbonic anhydrase (CA) inhibitor that inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Indisulam suppresses the expression of cyclin E and phosphorylation of CDK2, both of which are essential for the G1 to S transition.

Related Targets

Carbonic Anhydrase CDK